FAMDF
Futura Medical plc·Healthcare
0.00
52.222%(−0.00)
Close PriceLast Updated: — ET
52W L: $0.0052W H: $0.20
FAMDF NEWS
seekingalpha.com
May 4
Futura Medical plc (FAMDF) Q4 2025 Earnings Call Transcript
Futura Medical plc (FAMDF) Q4 2025 Earnings Call Transcript
proactiveinvestors.com
Apr 29
Microsoft Q3 results top expectations, driven by Intelligent Cloud strength
Microsoft Corp (NASDAQ:MSFT) reported fiscal third quarter earnings that exceeded Wall Street expectations, driven by continued strength in its cloud and...
proactiveinvestors.com
Apr 29
Futura Medical refines strategy and evolves commercial model after tough 2025
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind erectile dysfunction gel Eroxon, said it has refined its strategy...
proactiveinvestors.co.uk
Apr 29
Futura Medical refines strategy and evolves commercial model after tough 2025
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind erectile dysfunction gel Eroxon, said it has refined its strategy and is evolving its commercial model following a comprehensive strategic review. In its full-year results statement, the told investors it is moving from a pure out-licensing structure toward a hybrid model combining research and development with direct commercial activity.
proactiveinvestors.com
Mar 24
Gold just had one of its worst weeks in 40 years. Is it time to buy the dip?
The metal dropped 17% in five trading days, briefly erasing all of its 2026 gains. The sell-off looks dramatic. The case for holding is stronger than it...
proactiveinvestors.co.uk
Mar 23
Futura Medical reports positive trial results for upgraded erectile dysfunction gel
The consumer healthcare company's new Intense formula showed stronger early effects than its existing product in a 223-person study Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the Eroxon erectile dysfunction gel, has reported positive results from a home user trial of both its existing product and a new, stronger formulation called Eroxon Intense. The study, conducted over four weeks with 223 male participants aged 18 to 59, found the product delivered high efficacy rates in men with mild to moderate erectile dysfunction (ED), a condition affecting the ability to achieve or maintain an erection.
